Moderna's mRNA Melanoma Vaccine Shows Promising Phase 3 Results
Moderna and Merck announced promising results for their personalized mRNA melanoma vaccine, intismeran autogene (mRNA-4157), in a Phase 3 trial. The combination of the vaccine with Merck's immunotherapy drug Keytruda reduced the risk of cancer returning or spreading in high-risk melanoma patients. This breakthrough marks one of the biggest advancements yet for mRNA cancer treatments.
The study enrolled over 1,100 patients with stage IIB through stage IV melanoma whose tumors had been completely removed through surgery. Researchers found that patients receiving the personalized vaccine plus Keytruda experienced statistically significant improvements in recurrence-free survival and distant metastasis-free survival compared to those who received Keytruda alone.
The vaccine is designed specifically for each patient's tumor, using genetic analysis to create a custom mRNA vaccine targeting unique mutations. While the Phase 3 trial results are encouraging, the vaccine has not yet been approved by the FDA. Moderna and Merck plan to present the full data to regulators and pursue approval filings.